

Advances in Experimental Medicine and Biology 721

L. Ashley Cowart *Editor*

Sphingolipids and Metabolic Disease

LANDES
BIOSCIENCE

 Springer

Sphingolipids and Metabolic Disease

ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY

Editorial Board:

NATHAN BACK, *State University of New York at Buffalo*

IRUN R. COHEN, *The Weizmann Institute of Science*

ABEL LAJTHA, *N.S. Kline Institute for Psychiatric Research*

JOHN D. LAMBRIS, *University of Pennsylvania*

RODOLFO PAOLETTI, *University of Milan*

Recent Volumes in this Series

Volume 712

CYSTEINE PROTEASES OF PATHOGENIC ORGANISMS

Mark W. Robinson and John P. Dalton

Volume 713

CELL FUSION IN HEALTH AND DISEASE, I: CELL FUSION IN HEALTH

Thomas Dittmar

Volume 714

CELL FUSION IN HEALTH AND DISEASE, II: CELL FUSION IN DISEASE

Thomas Dittmar

Volume 715

BACTERIAL ADHESION: BIOLOGY, CHEMISTRY AND PHYSICS

Dirk Linke and Adrian Goldman

Volume 716

MAST CELL BIOLOGY: CONTEMPORARY AND EMERGING TOPICS

Alasdair M. Gilfillan and Dean D. Metcalfe

Volume 717

KAINATE RECEPTORS: NOVEL SIGNALING INSIGHTS

Antonio Rodriguez-Moreno and Talvinder S. Sihra

Volume 718

BRAIN INSPIRED COGNITIVE SYSTEMS 2010

Ricardo Sanz, Jaime Gomez and Carlos Hernandez

Volume 719

HOT TOPICS IN INFECTION AND IMMUNITY IN CHILDREN VIII

Nigel Curtis

Volume 720

HUMAN CELL TRANSFORMATION

Johng S. Rhim and Richard Kremer

Volume 721

SPHINGOLIPIDS AND METABOLIC DISEASE

L. Ashley Cowart

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

Sphingolipids and Metabolic Disease

Edited by

L. Ashley Cowart, PhD

*Department of Biochemistry and Molecular Biology, Medical University
of South Carolina, and Ralph H. Johnson Veteran's Administration,
Charleston, South Carolina, USA*

Springer Science+Business Media, LLC

Landes Bioscience

Springer Science+Business Media, LLC
Landes Bioscience

Copyright ©2011 Landes Bioscience and Springer Science+Business Media, LLC

All rights reserved.

No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system; for exclusive use by the Purchaser of the work.

Printed in the USA.

Springer Science+Business Media, LLC, 233 Spring Street, New York, New York 10013, USA
<http://www.springer.com>

Please address all inquiries to the publishers:
Landes Bioscience, 1806 Rio Grande, Austin, Texas 78701, USA
Phone: 512/ 637 6050; FAX: 512/ 637 6079
<http://www.landesbioscience.com>

The chapters in this book are available in the Madame Curie Bioscience Database.
<http://www.landesbioscience.com/curie>

Sphingolipids and Metabolic Disease, edited by L. Ashley Cowart. Landes Bioscience / Springer Science+Business Media, LLC dual imprint / Springer series: Advances in Experimental Medicine and Biology.

ISBN: 978-1-4614-0649-5

While the authors, editors and publisher believe that drug selection and dosage and the specifications and usage of equipment and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they make no warranty, expressed or implied, with respect to material described in this book. In view of the ongoing research, equipment development, changes in governmental regulations and the rapid accumulation of information relating to the biomedical sciences, the reader is urged to carefully review and evaluate the information provided herein.

Library of Congress Cataloging-in-Publication Data

Sphingolipids and metabolic disease / edited by L. Ashley Cowart.

p. ; cm. -- (Advances in experimental medicine and biology ; v. 721)

Includes bibliographical references.

ISBN 978-1-4614-0649-5

1. Sphingolipidoses. 2. Sphingolipids--Pathophysiology. I. Cowart, Lauren Ashley. II. Series: Advances in experimental medicine and biology ; v. 721. 0065-2598

[DNLM: 1. Metabolic Diseases--pathology. 2. Sphingolipids--metabolism. W1 AD559 v.721 2011 / WD 200] RC632.S67S64 2011

616.3'9--dc23

2011021157

PREFACE

Recent years have witnessed an explosion in the incidence of obesity and its sequelae including Type 2 diabetes and the metabolic syndrome. While originally confined to developed countries, increasing prosperity in developing countries has broadened the worldwide incidence of these disorders. Moreover, while diagnoses of Type 2 diabetes were originally almost exclusively confined to adult populations, the rise in childhood obesity has precipitated a marked increase of this disorder in children. Thus, it is crucial to explore all possible therapeutic and preventive methods to attenuate pathological processes associated with these disorders.

Current thinking holds that obesity derives primarily from overnutrition (though compelling arguments for other mechanisms, for example, endocrine disruption by environmental pollutants, also gain support from the literature). In animals, overnutrition is initially handled by adipose tissue expansion; however, exhaustion of this route of lipid sequestering results in oversupply of lipid to other tissues including skeletal muscle, heart, liver, and others. Failure of these tissues to clear excess lipids through either metabolism or sequestration into putatively inert triacylglycerols results in perturbation of bioactive lipid metabolism in cells. In particular, aberrant generation of bioactive sphingolipids is implicated in a multitude of pathological outcomes of metabolic disease including insulin resistance, inflammation, cardiomyopathy, and others. This volume addresses not only the fundamentals of sphingolipid metabolism and analysis, but also the roles of sphingolipids in these disease processes.

Chapter 1: *Sphingolipid Metabolism and Analysis in Metabolic Disease*, by Sarah E. Brice and L. Ashley Cowart. This chapter presents an overview of sphingolipid metabolism and its regulation, followed by caveats and technical considerations for sphingolipid measurement.

Chapter 2: *Sphingolipids and Cardiovascular Diseases*, by Xian-Cheng Jiang, Ira J. Goldberg, and Tae-Sik Park. This chapter addresses current knowledge of the roles of sphingolipids in dysfunction of the cardiovascular system including lipoprotein metabolism, atherosclerosis, and cardiomyopathy.

Chapter 3: *Heart Sphingolipids in Health and Disease*, by Marcin Baranowski and Jan Górski. This chapter continues the cardiovascular theme by addressing novel

mechanisms of regulating sphingolipid biosynthesis in the heart in diabetes as well as the protective role of sphingolipids in ischemia/reperfusion injury.

Chapter 4: *Blood Sphingolipids in Homeostasis and Pathobiology*, by Samar M. Hammad. This chapter addresses the clinical assessment of blood sphingolipids for diagnostic purposes.

Chapter 5: *Adipose Tissue and Ceramide Biosynthesis in the Pathogenesis of Obesity*, by Fahumiya Samad, Leylla Badeanlou, Charmi Shah, and Guang Yang. This chapter discusses changes in sphingolipids that occur as a result of obesity and how these changes mediate inflammation and cardiovascular risk.

Chapter 6: *Sphingolipids and Hepatic Steatosis*, by Benjamin T. Bikman and Scott A. Summers. This chapter discusses how manipulation of sphingolipid metabolism influences triacylglycerol metabolism in the context of fatty liver.

Chapter 7: *Glycosphingolipids and Insulin Resistance*, by Johannes M. Aerts and colleagues. This chapter discusses the roles of glycosphingolipids in insulin signaling and how pharmacological reduction of glycosphingolipid synthesis ameliorates symptoms of the metabolic syndrome.

Chapter 8: *Glycosphingolipids and Kidney Disease*, by Andrew R. Mather and Leah J. Siskind. This chapter continues a focus on glycosphingolipids in the context of kidney pathology. Although the implication of glycosphingolipids in kidney disease associated with diabetes is still conjectural, the role these lipids play in a spectrum of kidney disorders, as discussed in this chapter, justifies further investigation in this highly novel and underexplored area.

Chapter 9: *Sphingolipid Synthetic Pathways are Major Regulators of Lipid Homeostasis*, by Tilla S. Worgall. This final chapter presents compelling findings that sphingolipids may regulate cholesterol homeostasis through SREBP and lipid efflux. The cross-talk between sphingolipids and lipoprotein metabolism presents rich opportunities for therapeutics aimed at ameliorating dyslipidemia associated with metabolic syndrome that promotes atherosclerosis.

Our goal in this volume was to compile chapters presenting broad overviews of tissue-specific effects of sphingolipids, while emphasizing interrelatedness of cellular processes and cross-talk between organs.

We hope you enjoy the volume.

L. Ashley Cowart, PhD
Department of Biochemistry and Molecular Biology, Medical University
of South Carolina, and Ralph H. Johnson Veteran's Administration,
Charleston, South Carolina, USA

ABOUT THE EDITOR...



L. ASHLEY COWART obtained her BS in Biology in 1995 from Furman University in Greenville, South Carolina, and her PhD in Biochemistry in 2001 from Vanderbilt University in Nashville, Tennessee. After postdoctoral work in the laboratory of Dr. Yusuf Hannun, she joined the faculty at the Medical University of South Carolina in Charleston, South Carolina, where she currently holds the position of Assistant Professor of Biochemistry and Molecular Biology. Dr. Cowart's main research focus is the regulation of sphingolipid metabolism in diabetes and obesity and the roles of sphingolipids in pathological outcomes associated with these disorders. In addition to research, she is involved with graduate admissions and education.

PARTICIPANTS

Johannes M. Aerts
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Jan Aten
Academic Medical Center
Department of Pathology
University of Amsterdam
Amsterdam
The Netherlands

Leylla Badeanlou
Torrey Pines Institute for Molecular
Studies
San Diego, California
USA

Marcin Baranowski
Department of Physiology
Medical University of Białystok
Białystok
Poland

Florence M. Bietrix
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Nora Bijl
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Benjamin T. Bikman
Program in Cardiovascular
and Metabolic Disorders
Duke-NUS Graduate Medical School
Singapore

Rolf G. Boot
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Sarah E. Brice
Department of Biochemistry
and Molecular Biology
Medical University of South Carolina
Charleston, South Carolina
USA

L. Ashley Cowart
Department of Biochemistry
and Molecular Biology
Medical University of South Carolina
and
Ralph H. Johnson Veteran's Administration
Charleston, South Carolina
USA

Nick Dekker
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Marco van Eijk
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Ira J. Goldberg
Department of Medicine
Division of Preventive Medicine
and Nutrition
Columbia University
New York, New York
USA

Jan Górski
Department of Physiology
Medical University of Białystok
Białystok
Poland

Albert K. Groen
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Johanna Groener
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Samar M. Hammad
Department of Regenerative Medicine
and Cell Biology
Medical University of South Carolina
Charleston, South Carolina
USA

Xian-Cheng Jiang
Department of Cell Biology
State University of New York
Brooklyn, New York
USA

Mirjam Langeveld
Academic Medical Center
Department of Internal Medicine
University of Amsterdam
Amsterdam
The Netherlands

Elisa Lombardo
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Andrew R. Mather
Department of Medicine
Division of General Internal
Medicine/Geriatrics
Medical University of South Carolina
Charleston, South Carolina
USA

Roelof Ottenhoff
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Hermen S. Overkleeft
Leiden Institute of Chemistry
Department of Bioorganic Synthesis
Gorlaeus Laboratories
Leiden University
Leiden
The Netherlands

Tae-Sik Park
Lee Gil Ya Cancer and Diabetes Institute
Gachon University of Medicine
and Science
Inchon
South Korea

Cindy van Roomen
Academic Medical Center
Department of Medical Biochemistry
University of Amsterdam
Amsterdam
The Netherlands

Fahumiya Samad
Torrey Pines Institute for Molecular
Studies
San Diego, California
USA

Mireille Serlie
Academic Medical Center
Department of Internal Medicine
University of Amsterdam
Amsterdam
The Netherlands

Charmi Shah
Torrey Pines Institute for Molecular
Studies
San Diego, California
USA

Leah J. Siskind
Department of Medicine
Division of General Internal
Medicine/Geriatrics
Medical University of South Carolina
Charleston, South Carolina
USA

Scott A. Summers
Program in Cardiovascular
and Metabolic Disorders
Duke-NUS Graduate Medical School
Singapore
and
The Stedman Center for Nutrition
and Metabolism Research
Duke University Medical Center
Durham, North Carolina
USA

Tom Wennekes
Lieden Institute of Chemistry
Department of Bioorganic Synthesis
Gorlaeus Laboratories
Leiden University
Leiden
The Netherlands

Tilla S. Worgall
Department of Pathology
Columbia University
New York, New York
USA

Guang Yang
Torrey Pines Institute for Molecular
Studies
San Diego, California
USA

CONTENTS

1. SPHINGOLIPID METABOLISM AND ANALYSIS IN METABOLIC DISEASE	1
Sarah E. Brice and L. Ashley Cowart	
Abstract.....	1
Introduction	1
Sphingolipid Metabolism.....	3
Sphingolipids and Lipotoxicity	6
Approaches to the Study of Sphingolipids in Lipotoxicity	9
Conclusion	11
2. SPHINGOLIPIDS AND CARDIOVASCULAR DISEASES: LIPOPROTEIN METABOLISM, ATHEROSCLEROSIS AND CARDIOMYOPATHY.....	19
Xian-Cheng Jiang, Ira J. Goldberg and Tae-Sik Park	
Abstract.....	19
Introduction	19
Sphingolipid Biosynthesis.....	20
Role of Sphingomyelin (SM) in Lipoprotein Metabolism	22
Sphingomyelin and Atherosclerosis.....	24
Ceramide in Lipotoxic Cardiomyopathy	31
Conclusion	32
3. HEART SPHINGOLIPIDS IN HEALTH AND DISEASE	41
Marcin Baranowski and Jan Górski	
Abstract.....	41
Introduction	41
Characterization of Myocardial Sphingolipid Metabolism	43
PPARs as Regulators of Sphingolipid Metabolism in the Heart	44
Exercise Modulates Myocardial Ceramide Metabolism	45

Sphingolipids in Ischemia/Reperfusion Injury of the Heart.....	48
Ceramide as a Mediator of Lipotoxicity in the Heart.....	50
Conclusion and Future Prospects.....	54

4. BLOOD SPHINGOLIPIDS IN HOMEOSTASIS AND PATHOBIOLOGY57

Samar M. Hammad

Abstract.....	57
Introduction.....	57
Blood Sphingolipids in Homeostasis.....	58
Blood Sphingolipids in Pathobiology.....	60
Conclusion.....	63

5. ADIPOSE TISSUE AND CERAMIDE BIOSYNTHESIS IN THE PATHOGENESIS OF OBESITY.....67

Fahumiya Samad, Leylla Badeanlou, Charmi Shah and Guang Yang

Abstract.....	67
Introduction.....	67
Remodeling of Adipose and Plasma Ceramide in Obesity.....	69
Regulation of Ceramide Metabolism in Obesity.....	71
Novel Links Between Sphingolipid Metabolism and Plasminogen Activator Inhibitor 1 (PAI-1).....	72
Contribution of Ceramide Biosynthesis to Body Weight Regulation and Energy Metabolism.....	73
Sphingolipids as Mediators of Adipose Inflammation in Obesity.....	74
Contribution of Ceramide Biosynthesis to Obesity Mediated Insulin Resistance.....	75
Contribution of Ceramide Biosynthesis to Hepatic Steatosis.....	77
Ceramide and Cardiovascular Disease.....	79
Conclusion.....	80

6. SPHINGOLIPIDS AND HEPATIC STEATOSIS.....87

Benjamin T. Bikman and Scott A. Summers

Abstract.....	87
Introduction.....	87
Sphingolipid Levels in the Steatotic Liver.....	89
Modulation of Sphingolipid Synthesis Impacts Hepatic Steatosis.....	89
Factors Associated with NAFLD Induce Sphingolipid Synthesis.....	91
Possible Mechanisms.....	94
Conclusion.....	94

7. GLYCOSPHINGOLIPIDS AND INSULIN RESISTANCE99

Johannes M. Aerts, Rolf G. Boot, Marco van Eijk, Johanna Groener, Nora Bijl,
 Elisa Lombardo, Florence M. Bietrix, Nick Dekker, Albert K. Groen,
 Roelof Ottenhoff, Cindy van Roomen, Jan Aten, Mireille Serlie,
 Mirjam Langeveld, Tom Wennekes and Hermen S. Overkleeft

Abstract.....	99
Introduction.....	100
Insulin Resistance.....	100
Glycosphingolipids.....	103
(Glyco)Sphingolipids and Insulin Resistance.....	107
Pharmacological Modulation of Glycosphingolipids and Insulin Resistance.....	110
Conclusion.....	113

8. GLYCOSPHINGOLIPIDS AND KIDNEY DISEASE121

Andrew R. Mather and Leah J. Siskind

Abstract.....	121
Introduction.....	121
Metabolism of Sphingolipids.....	122
Metabolism of Glycosphingolipids.....	123
Glycosphingolipid Subcellular Localization and Transport.....	125
Functions of Glycosphingolipids.....	125
Fabry's Disease.....	127
Polycystic Kidney Disease.....	127
Kidney Cancer.....	128
Glomerulonephritis.....	129
Diabetic Nephropathy and Metabolic Syndrome.....	130
Conclusion.....	131

9. SPHINGOLIPID SYNTHETIC PATHWAYS ARE MAJOR REGULATORS OF LIPID HOMEOSTASIS139

Tilla S. Worgall

Abstract.....	139
Introduction.....	140
SREBPs are Key Transcription Factors of Protein That Synthesize Cholesterol, Fatty Acids and Phospholipids.....	140
Sphingolipids Synthesis is Required to Increase SREBP in Lipid Depletion.....	140
Cholesterol, Unsaturated Fatty Acids and Ceramides Inhibit SREBP.....	142
ABCA1 and ABCG1 are Key Lipid Efflux Receptors That Determine Anti-Atherogenic High-Density Lipoprotein (HDL) Levels.....	143
Sphingolipids Affect ABCA1 and ABCG1 by Different Mechanisms.....	143
Sphingomyelin Induces Lipoprotein Patterns That Correlate with Increased Cardiovascular Risk.....	145
Conclusion.....	146

INDEX.....149

ACKNOWLEDGEMENTS

The Editor wishes to acknowledge funding from the Department of Veteran's Affairs and the NIH Cobre in Lipidomics and Pathobiology at the Medical University of South Carolina. She also wishes to acknowledge her PhD mentor, Dr. Jorge Capdevila, at Vanderbilt University, for his patience and adherence to the highest standards for science in lipid biochemistry. In addition, this work would not have been possible without the training, mentorship, and continued support from Dr. Yusuf A. Hannun and Dr. Lina M. Obeid.

SPHINGOLIPID METABOLISM AND ANALYSIS IN METABOLIC DISEASE

Sarah E. Brice^{*,1} and L. Ashley Cowart^{1,2}

¹*Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, USA;*

²*Ralph H. Johnson Veteran's Administration, Charleston, South Carolina, USA*

**Corresponding Author: Sarah E. Brice—Email: brices@musc.edu*

Abstract: Sphingolipids are an important class of structural and signaling molecules within the cell. As sphingolipids have been implicated in the development and pathogenesis of insulin resistance and the metabolic syndrome, it is important to understand their regulation and metabolism. Although these lipids are initially produced through a common pathway, there is no “generic” sphingolipid. Indeed, the biophysical and signaling properties of lipids may be manipulated by the subunit composition or isoform of their synthetic enzymes, via regulation of substrate integration. Functionally distinct pools of chemically-equivalent lipids may also be generated by de novo synthesis and recycling of existing complex sphingolipids. The highly integrated metabolism of the many bioactive sphingolipids means that manipulation of one enzyme or metabolite can result in a ripple effect, causing unforeseen changes in metabolite levels, enzyme activities, and cellular programmes. Fortunately, a suite of techniques, ranging from thin-layer chromatography to liquid chromatography-mass spectrometry approaches, allows investigators to undertake a functional characterization of all or part of the sphingolipidome in their systems of interest.

INTRODUCTION

Mammalian sphingolipid metabolism consists of a complex network of interlocking pathways (Fig. 1). The basic currency of sphingolipid metabolism is the sphingoid base (1,3-dihydroxy-2-amino-alkane and its derivatives); this base may be subject to the addition of a fatty acid, head group, or phosphate moiety (reviewed in refs. 1-3). This intricate




Figure 1. Metabolism of simple sphingolipids.